TransCode Therapeutics Inc. (NASDAQ:RNAZ) Short Interest Update

TransCode Therapeutics Inc. (NASDAQ:RNAZ) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 56,527 shares, an increase of 100.9% from the May 31st total of 28,142 shares. Based on an average daily trading volume, of 230,735 shares, the days-to-cover ratio is currently 0.2 days. Currently, 6.0% of the company’s shares are sold short.

TransCode Therapeutics Trading Up 18.5%

NASDAQ:RNAZ traded up $0.97 during trading hours on Tuesday, hitting $6.21. The stock had a trading volume of 51,317 shares, compared to its average volume of 152,712. The company has a market cap of $5.90 million, a PE ratio of -0.12 and a beta of 1.29. The business has a 50 day simple moving average of $6.34 and a two-hundred day simple moving average of $8.05. TransCode Therapeutics has a 1-year low of $3.82 and a 1-year high of $20.99.

TransCode Therapeutics (NASDAQ:RNAZ) last released its quarterly earnings results on Friday, May 15th. The company reported ($21.28) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of TransCode Therapeutics in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.